Read on Twitter
So here's an update on the abandoned UQ COVID vaccine named UQ-CSL v451 https://www.uq.edu.au/news/node/127942
First, the release states that the vaccine worked: vaccine elicited a response and "There were no serious adverse events or safety concerns reported in the 216 trial participants"
BUT the vaccine trials will not advance to Phase 2/3, according to @CSL
The problem: Ph 1 data showed the generation of antibodies against fragments of a protein (gp41), a HIV-derived construct used to "stabilise the vaccine".
This was anticipated and "participants were informed of the possibility of a partial immune response to this component"
This was anticipated and "participants were informed of the possibility of a partial immune response to this component"
Perhaps this alone isn't an issue? After all the Oxford / @AstraZeneca COVID vaccine would also result in antibodies against the chimpanzee adenovirus vector.
The concern was that this resulted in "levels induced would interfere with certain HIV tests".
So the immune response itself is not an issue, it's that those vaccinated would test false-positive to HIV in certain tests.
So the immune response itself is not an issue, it's that those vaccinated would test false-positive to HIV in certain tests.
Up-front HIV screening is primarily ELISA-based, testing against antigens (such as that described above).
BUT positive HIV tests are re-confirmed, using a second assay:
http://hivinsite.ucsf.edu/insite?page=kb-02-02-01
BUT positive HIV tests are re-confirmed, using a second assay:
http://hivinsite.ucsf.edu/insite?page=kb-02-02-01
However it was concluded that "significant changes would need to be made to well-established HIV testing procedures in the healthcare setting to accommodate rollout of this vaccine."
So what is this 'HIV component' of UQ-CSL v451?
Side-note: the vaccine contains "MF59" - an immunologic adjuvant that uses squalene, owned by @NovartisScience
Side-note: the vaccine contains "MF59" - an immunologic adjuvant that uses squalene, owned by @NovartisScience
The vaccine itself relies on a SARS-CoV-2 spike protein construct that is different from those in the Pfizer/Modern/AZ vaccines.
Instead the use a 'molecular clamp technology' to 'lock' the Spike in the pre-fusion conformation.
Instead the use a 'molecular clamp technology' to 'lock' the Spike in the pre-fusion conformation.
The purified stablized ('clamped') spike protein is then formulated in vaccine.
Again: this is different to Pfizer/Modern/AZ vaccines that deliver the genetic code for spike protein to be produced in host cells in order to stimulate an immune response.
Again: this is different to Pfizer/Modern/AZ vaccines that deliver the genetic code for spike protein to be produced in host cells in order to stimulate an immune response.
So what's the deal with the clamp? Plenty of detail here: https://www.publish.csiro.au/ma/Fulltext/ma20028
The UQ team have engineered clamps for a range of viruses (red, below), that can be adapted as needed to engineered stable viral proteins for a range of diseases.
https://eurekalert.org/multimedia/pub/190249.php?from=417520
https://eurekalert.org/multimedia/pub/190249.php?from=417520
In the case of the SARS2 spike construct, the 'clamp' is engineered from HIV gp41 - and would be exposed and immunogenic, just like the SARS2 spike epitopes.
Diving into 'molecular clamp' technology articles, I can't find the specific reference to HIV or gp41 constructs, and this may have been proprietary until it was disclosed today.
gp41 itself is a transmembrane subunit of the envelope protein complex of retroviruses
https://en.wikipedia.org/wiki/Gp41
https://en.wikipedia.org/wiki/Gp41
And that is the 'red' part at the bottom in the graphic below.
This is is a pre-print article describing the vaccine ; the nature/origin of the molecular clamp is not directly stated, but protein is purified with "the anti-clamp mAb HIV1281" - so it's structural and used as an antigen for purification.
https://www.researchsquare.com/article/rs-68892/v1
https://www.researchsquare.com/article/rs-68892/v1
This paper includes rat, ferret and hamster data, but they don't appear to disclose any evaluation of HIV ELISA assay positivity in this paper - not clear whether they tested for it and decided not to disclose, or it only appeared in the human studies.
Most translational science program are not successful, because biology is complicated, but we are working to get better at it. Shout-out to the @UQ_News and @CSL scientists who engineered a vaccine in months and took it into clinical trials. Remarkable. @ProfPaulYoung
